These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 8666736

  • 1. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM.
    J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
    [No Abstract] [Full Text] [Related]

  • 2. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
    Tancer RS.
    Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
    [Abstract] [Full Text] [Related]

  • 3. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
    Burshtein S.
    Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
    [No Abstract] [Full Text] [Related]

  • 4. Drug patent protection: how long is long enough?
    Sibbald B.
    CMAJ; 2001 May 01; 164(9):1331. PubMed ID: 11341146
    [No Abstract] [Full Text] [Related]

  • 5. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J.
    Int J Health Serv; 1993 May 01; 23(1):147-60. PubMed ID: 8425783
    [Abstract] [Full Text] [Related]

  • 6. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A.
    Food Drug Law J; 2003 May 01; 58(4):711-40. PubMed ID: 15027457
    [No Abstract] [Full Text] [Related]

  • 7. Rx: higher prices.
    Kosterlitz J.
    Natl J (Wash); 1993 Feb 13; 25(7):396-9. PubMed ID: 10125572
    [Abstract] [Full Text] [Related]

  • 8. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS.
    Seton Hall Law Rev; 2003 Feb 13; 33(2):479-510. PubMed ID: 12715807
    [No Abstract] [Full Text] [Related]

  • 9. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA.
    Food Drug Law J; 2000 Feb 13; 55(3):321-41. PubMed ID: 11824464
    [No Abstract] [Full Text] [Related]

  • 10. A license to print money?
    Nat Biotechnol; 2006 Jun 13; 24(6):593. PubMed ID: 16763570
    [No Abstract] [Full Text] [Related]

  • 11. India remains on US trade "priority watch list" for failing to uphold international drug company patents.
    Arie S.
    BMJ; 2013 May 08; 346():f2949. PubMed ID: 23657189
    [No Abstract] [Full Text] [Related]

  • 12. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M.
    N Engl J Med; 2006 Sep 28; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract] [Full Text] [Related]

  • 13. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT.
    J Contemp Health Law Policy; 2006 Sep 28; 22(2):383-408. PubMed ID: 17117702
    [No Abstract] [Full Text] [Related]

  • 14. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 28; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

  • 15. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 28; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 16. It is not unethical, though it is often unwise, to override patents.
    Leventer H.
    Am J Bioeth; 2002 Dec 28; 2(3):50-1. PubMed ID: 12230860
    [No Abstract] [Full Text] [Related]

  • 17. Compulsory licensure: the case of Cipro and beyond.
    Chakrabarty AM.
    Am J Bioeth; 2002 Dec 28; 2(3):40. PubMed ID: 12230853
    [No Abstract] [Full Text] [Related]

  • 18. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S.
    Fla J Int Law; 2002 Dec 28; 14(2):217-60. PubMed ID: 16526138
    [No Abstract] [Full Text] [Related]

  • 19. Patents: the public interest versus the private privilege.
    Parsi KP, Egan EA.
    Am J Bioeth; 2002 Dec 28; 2(3):45-6. PubMed ID: 12230857
    [No Abstract] [Full Text] [Related]

  • 20. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB.
    Food Drug Law J; 1999 Dec 28; 54(2):185-6. PubMed ID: 11759712
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.